15 / 30
SELECT Trial
15
•
Lenvatinib, an oral multi-tyrosine kinase inhibitor of
VEGFR1-3,
FGFR1-4, PDGFRα, RET, and KIT
, demonstrated efficacy in a phase 2 study of patients with
RR-DTC
8,9
– This phase 3
S
tudy of (
E
7080)
LE
nvatinib in Differentiated
C
ancer of the
T
hyroid (
SELECT
) was conducted
to assess the progression-free survival of patients with RR-DTC treated with lenvatinib versus placebo
RR-DTC, radioiodine-refractory differentiated thyroid cancer.
1. Sherman S et al.
J Clin Oncol.
2011;29S:5503
2. Cabanillas M et al.
Clin Cancer Res.
Manuscript submitted
Schlumberger M, et al. N Engl J Med 2015;372:621-30. DOI: 10.1056/NEJMoa1406470